Neokestose suppresses the growth of human melanoma A2058 cells via inhibition of the nuclear factor‑κB signaling pathway

Wu,Jiann‑Shing; Chang,Jan‑Yi; Chen,C. Will; Lin,Ming‑Tse; Sheu,Dey‑Chyi; Lee,Shun‑Mei

doi:10.3892/mmr.2017.6594

Neokestose suppresses the growth of human melanoma A2058 cells via inhibition of the nuclear factor‑κB signaling pathway

Authors:
- Jiann‑Shing Wu
- Jan‑Yi Chang
- C. Will Chen
- Ming‑Tse Lin
- Dey‑Chyi Sheu
- Shun‑Mei Lee
View Affiliations

Affiliations: Department of Styling and Cosmetology, Hsin Shen Junior College of Medical Care and Management, Taoyuan 325, Taiwan, R.O.C., Department of Bioengineering, Tatung University, Taipei 104, Taiwan, R.O.C.
Published online on: May 17, 2017 https://doi.org/10.3892/mmr.2017.6594
Pages: 295-300

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neokestose has superior prebiotic effects compared with the commercial fructooligosaccharides (FOS). In addition, the branched structure of neokestose, a type of neo‑FOS, confers improved chemical stability compared with conventional FOS; therefore, the investigation of the branched structure by the present study may be of high biomedical value. The present study aimed to determine whether neokestose may suppress growth of the A2058 melanoma cell line. The cells were initially treated with neokestose; subsequently, in vitro cytotoxicity was assessed using MTT, and cell cycle progression and apoptosis were detected using flow cytometry. The protein expression levels of cyclin D1, phosphorylated (p)‑inhibitor of κB (IκB) and nuclear factor‑κB (NF‑κB) were determined using western blotting. Treatment with neokestose led to a dose‑dependent inhibition of cell viability. Flow cytometry data indicated that neokestose increased the sub‑G1 cell population, and induced early and late apoptosis. Western blot analysis revealed that neokestose treatment reduced the expression levels of p‑IκB and cyclin D1. These findings suggest that neokestose treatment may induce suppression of A2058 melanoma cell viability via inhibition of the NF‑κB pathway. The present findings support the requirement for further investigation into the potential use of neokestose as an additional or chemopreventive therapeutic agent for the treatment of melanoma.

View Figures

View References

1	Eggermont AM, Spatz A and Robert C: Cutaneous melanoma. Lancet. 383:816–827. 2014. View Article : Google Scholar : PubMed/NCBI
2	Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y, Omoto D, Ohmori S, Haruyama S, Sawada Y, et al: Nivolumab in the treatment of malignant melanoma: Review of the literature. Onco Targets Ther. 8:2045–2051. 2015.PubMed/NCBI
3	Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, et al: Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study. Lancet Oncol. 8:733–740. 2013. View Article : Google Scholar
4	Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, et al: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 20:1867–1876. 2014. View Article : Google Scholar
5	Niezgoda A, Niezgoda P and Czajkowski R: Novel Approaches to treatment of advanced melanoma: A review on targeted therapy and immunotherapy. Biomed Res Int. 2015:8513872015. View Article : Google Scholar : PubMed/NCBI
6	Gandini S, Sera F, Cattanizza MS, Pasquini P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60. 2005. View Article : Google Scholar : PubMed/NCBI
7	Dhawan P, Singh AB, Ellis DL and Richmond A: Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 62:7335–7342. 2002.PubMed/NCBI
8	McNulty SE, Tohidian NB and Meyskens FL Jr: RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment Cell Res. 14:456–465. 2001. View Article : Google Scholar : PubMed/NCBI
9	McNulty SE, del Rosario R, Cen D, Meyskens FL Jr and Yang S: Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 17:173–180. 2004. View Article : Google Scholar : PubMed/NCBI
10	Schmitz ML, Mattioli I, Buss H and Kracht M: NF-kappaB: A multifaceted transcription factor regulated at several levels. Chembiochem. 5:1348–1358. 2004. View Article : Google Scholar : PubMed/NCBI
11	Gilmore TD: Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene. 51:6680–6684. 2006. View Article : Google Scholar
12	Sherr CJ and Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
13	Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J and Bartek J: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 56:5475–5483. 1996.PubMed/NCBI
14	Chin L, Merlino G and DePinho RA: Malignant melanoma: Modern black plague and genetic black box. Genes Dev. 12:3467–3481. 1998. View Article : Google Scholar : PubMed/NCBI
15	Filmus J, Robles AI, Shi W, Wong MJ, Colombo LL and Conti CJ: Induction of cyclin D1 overexpression by activated ras. Oncogene. 9:3627–3633. 1994.PubMed/NCBI
16	Sullivan RJ and Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 6:1297–1304. 2013. View Article : Google Scholar
17	Sauter ER, Yeo UC, von Stemm AV, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M and Bastian BC: Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 62:3200–3206. 2002.PubMed/NCBI
18	Gibson GR and Roberfroid MB: Dietary modulation of the human colonic microbiota: Introducing the concepts of prebiotics. J Nutr. 125:1401–1412. 1995.PubMed/NCBI
19	Lim JS, Lee JH, Kang SW, Park SW and Kim SW: Studies on production and physical properties of neo-FOS produced by co-immobilized Penicillium citrinum and neo-fructosyltransferase. Eur Food Res Technol. 225:457–462. 2007. View Article : Google Scholar
20	Kilian S, Kritzinger S, Rycroft C, Gibson G and du Preez J: The effects of the novel bifidogenic trisaccharide, neokestose, on the human colonic microbiota. World J Microbiol Biotechnol. 18:637–644. 2002. View Article : Google Scholar
21	Lee SM, Chang JY, Wu JS and Sheu DC: Antineoplastic effect of a novel chemopreventive agent, neokestose, on the Caco-2 cell line via inhibition of expression of nuclear factor-κB and cyclooxygenase-2. Mol Med Rep. 12:1114–1118. 2015.PubMed/NCBI
22	Kritzinger SM, Kilian SG, Potgieter MA and de Preez JC: The effect of production parameters on the synthesis of the prebiotic trisaccharide, neokestose, by Xanthophyllomyces dendrorhous (Phaffia rhodozyma). Enzyme Microb Technol. 32:728–737. 2003. View Article : Google Scholar
23	Sheu DC, Chang JY, Chen YJ and Lee CW: Production of high-purity neofructooligosaccharides by culture of Xanthophyllomyces dendrorhous. Bioresour Technol. 132:432–435. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 109:(Suppl). S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
25	Luqman S and Pezzuto JM: NFkappaB: A promising target for natural products in cancer chemoprevention. Phytother Res. 24:949–963. 2010.PubMed/NCBI
26	Gupta SC, Sundaram C, Reuter S and Aggarwal BB: Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 1799:775–787. 2010. View Article : Google Scholar : PubMed/NCBI
27	Lin YZ, Yao SY, Veach RA, Torgerson TR and Hawiger J: Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 270:14255–14258. 1995. View Article : Google Scholar : PubMed/NCBI
28	Ariga A, Namekawa J, Matsumoto N, Inoue J and Umezawa K: Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem. 277:24625–24630. 2002. View Article : Google Scholar : PubMed/NCBI
29	Chen C, Liu Y, Chen Y and Xu J: C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFκB in colon cancer cells and xenograft tumors. Cancer Biol Ther. 12:797–807. 2011. View Article : Google Scholar : PubMed/NCBI